3 Stocks We're Ready to Sell

LLY Chart
LLY Chart

However, both revenue and net income have been falling for years, thanks largely to losing patent protection on key drugs such as Zyprexa, Cymbalta, and Evista. In the next few years, other blockbuster names will join that list, including Cialis and Alitma. And now that biosimilars have finally made their way through the FDA, Lilly's top-selling insulins may soon find themselves competing against lower-cost alternatives.

Lilly isn't standing still. The company has made some serious efforts to cut costs and strengthen its pipeline with promising drugs that are aimed at treating a huge variety of diseases, including Alzheimer's disease, cancer, and arthritis. It's also been active at partnering with overseas companies, with hopes that their partnerships will bear fruit one day.

So it's not that Lilly can't succeed in the future, but with the stock trading at 43 times trailing earnings and a still pricey 23 times 2016 earnings, I think the market is pricing in too much hope and not discounting enough of the risk. Until we see some of its pipeline turn into revenue, I'm going to steer clear of the stock, especially when you consider there are better investments available on the markets today.

Todd Campbell : A lot of hype surrounds using marijuana as a therapy for all sorts of diseases, and following lackluster study results in treating cancer pain and mixed results for treating schizophrenia, marijuana play GW Pharmaceuticals may have a valuation that's just gotten too rich.

GW Pharmaceuticals is undeniably at the forefront of researching marijuana's therapeutic potential, but I'm not convinced the company will be able to validate its effectiveness in large enough patient populations to warrant a billion dollar-plus market cap.

In January, a trial evaluating GW Pharmaceuticals' THC drug Sativex in cancer pain failed to outperform a sugar pill, casting doubt on its use in that large market. More recently, GW Pharmaceuticals reported results from a schizophrenia trial that, while interesting, were a bit lacking.

Following data from those trials, pressure mounts on the company to deliver positive results for its marijuana therapy for childhood epilepsy. Data should be coming in on that indication, but given the risk of another lackluster outcome and the fact that the indications being studied are for small patient pools, it may be worth ringing the register on this one if you're sitting on a profit.

George Budwell :GlaxoSmithKline plc is a Big Pharma stock that comes with brand recognition and a massive dividend yield of nearly 6%. Even so, I would caution investors against owning this dividend stock right now.

The company is facing a potentially steep drop-off in revenue because its aging asthma blockbuster, Advair, is likely to soon face generic competition in the U.S., and its newer respiratory medicines such as Anoro and Breo Ellipta don't appear capable of picking up the torch.

In fact, Breo Ellipta just failed to meet its primary endpoint in a late-stage study designed to assess the drug's ability to reduce the risk of cardiovascular death in COPD patients. This study would have greatly helped Breo Ellipta to differentiate itself from competitors and potentially capture a far larger market share.

Glaxo has been plagued by similar setbacks seemingly across its entire clinical pipeline of late, putting it in a precarious situation when it comes to replenishing its revenue stream going forward.

In turn, the drugmaker's hefty dividend yield is looking increasingly unsustainable. If the company doesn't lower its dividend or quickly find another major source of revenue, for instance, Glaxo's payout could become unsustainable (in fact, its cash payout ratio, which is the percentage of free cash flow paid out in dividends, was over 100% over the trailing-12 months -- not a good sign, as you usually want to see sub-80%).

All told, Glaxo simply doesn't offer much in the way of growth, and its dividend appears slated for a major reduction in the near term.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article 3 Stocks We're Ready to Sell originally appeared on

Brian Feroldi has no position in any stocks mentioned. George Budwell has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More